Document Detail


Assessment of Fetal Cardiac Function Using Tissue Doppler Techniques.
MedLine Citation:
PMID:  22626950     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Objective: Tissue Doppler echocardiography is being increasingly used in fetal medicine as a clinical and research tool. The objective of this study was to review the current status of tissue Doppler imaging (TDI) techniques applied to the fetus. Methods: Fetal cardiac function was evaluated using spectral and color TDI modes in normal fetuses and in several clinical conditions. Results: Annular peak velocities and their ratios as well as the myocardial performance index were evaluated using spectral TDI, and changes throughout gestation were described. Color TDI has several limitations in fetal life, particularly the use of low frame rates with current methods of acquisition and the lack of normal references for deformation parameters. Conclusions: Despite its limitations, TDI is a sensitive and promising method to evaluate fetal cardiac function.
Authors:
Montse Comas; Fatima Crispi
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-5-23
Journal Detail:
Title:  Fetal diagnosis and therapy     Volume:  -     ISSN:  1421-9964     ISO Abbreviation:  -     Publication Date:  2012 May 
Date Detail:
Created Date:  2012-5-25     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9107463     Medline TA:  Fetal Diagn Ther     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
Copyright © 2012 S. Karger AG, Basel.
Affiliation:
Servei de Ginecologia i Obstetrícia, Corporació Sanitària Parc Taulí, Sabadell, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  An Automated Computational Framework for Retinal Vascular Network Labeling and Branching Order Analy...
Next Document:  Intranasal insulin-like growth factor I (IGF-I) as a plausible future treatment of depression.